Please assess the completion status of the following clinical trial:

Trial Title: Vancomycin Versus Daptomycin for the Treatment of Methicillin Resistant Staphylococcus Aureus (MRSA) Bacteremia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 21 years.~* Inpatient at the time of enrolment.~* MRSA bacteremia due to MRSA isolates with a vancomycin MIC \> 1.5 ug/ml.~* Be prepared to undergo all treatments and procedures, and attend follow-ups as per the trial protocol.~Exclusion Criteria:~* Allergy to any of the study medications.~* Pregnant or breastfeeding females.~* Unable to provide consent or have no legally authorized representatives.~* Currently enrolled or within the past three months participated in an interventional antibiotic or vaccine trial.~* \>48 hours after MRSA vancomycin MIC \> or equal to1.5 ug/ml confirmation by the microbiology laboratory (assessed from time of lab report).~* Patients on palliative care or with less than 24 hours of life expectancy (as discussed with their primary physicians).~* Polymicrobial bacteremia \[see (a) below\].~* Pneumonia \[see (b) below\].~* On treatment with linezolid, tigecycline or ceftaroline immediately prior to enrolment.~* Previous blood cultures positive for MRSA in the preceding one month.~* On vancomycin or daptomycin treatment for more than 96 hours prior to enrolment.~* BSI due to MRSA with vancomycin MIC \> or equal to 4 ug/ml.~* Baseline serum creatine kinase more than 1.5 times the upper limit of normal.~* Patients with prosthetic heart valves~* Any other significant condition that would, in the opinion of the investigator, compromise the patient's safety or outcome in the trial.~  1. .Isolation of a significant organism other than MRSA from index blood cultures or blood cultures taken up to two weeks prior to enrolment and/or for which the patient is still on treatment.~ 2. .Chest x-ray at baseline consistent with pneumonia AND at least 2 of the following signs and symptoms: New onset or worsening cough, purulent sputum or increased suctioning requirements, dyspnea/tachypnea or respiratory rate \> 30/min, hypoxemia or worsening gas exchange as determined by study investigator.)

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Daptomycin (Type: EXPERIMENTAL): Daptomycin will be dosed intravenously at 6-8mg/kg every 24 hours.~Patients with uncomplicated bacteremia will receive a dose of 6mg/kg every 24 hours. Patients with suspected complicated bacteremia or endocarditis, or receipt of at least two doses of vancomycin in the last 90 days (apart from vancomycin received for their current MRSA bacteremia) will receive a dose of 8mg/kg every 24 hours.~In patients with a creatinine clearance less than 30ml/min, or on intermittent or continuous hemodialysis, daptomycin will be dosed at 6-8mg/kg every 48 hours. The same criteria as above applies as to whether they receive 6mg/kg or 8mg/kg every 48hours. Daptomycin will be administered after hemodialysis in patients undergoing intermittent hemodialysis.
- Vancomycin (Type: ACTIVE_COMPARATOR): Vancomycin will be dosed at 15mg/kg every 12 hours with appropriate dose adjustments by a pharmacist in patients with a creatinine clearance less than 50 ml/min, so as to achieve a vancomycin trough level of 15-20ug/ml.

Based on this trial design, predict the completion outcome and termination type (if applicable).